Search
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … [A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, MATE 1 InhibitorsProducts: 1 RayvowTaurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigationalTaurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid [taurine]. … It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis.
Categories: Heterocyclic Compounds, 1-RingProducts: Taurolin (Taurolidin "Geistlich") 2% - InstillationslösungPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalAlthough multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsPancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigationalPancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion.
Mixtures: KREON MIKRO 5000 IU MINIMIKROSFER,, Creon 8 CapBezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds, 2-RingTolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnWhile it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.
Categories: Drugs Used in DiabetesDitiocarb zinc
go.drugbank.com/drugs/DB14193ApprovedDitiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen. … Sensitivity to ditiocarb zinc may be identified with a clinical patch test.
Categories: Compounds used in a research, industrial, or household setting, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseSynonyms: Zinc N,N-diethyldithiocarbamate, Zinc, bis(diethylcarbamodithioato-S,S')-Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival. … [A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer
Mixtures: Avmapki Fakzynja Co-packCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesViomycin Action Pathway
smpdb.ca/view/SMP0126771Drug actionViomycin is an antibiotic used to treat Mycobacterium tuberculosis and binds to the ribosome displacing structures leading to inhibition of protein synthesis. It binds to the interface between helix 44 of the small ribosomal subunit and ...
Drugs: ViomycinEnzymes: 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyAAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: ANAGRELID RATIO 1 MG, Anagrelid Nordic 1 mg Tabletten